Biopharma delivered strong revenue growth, up 9.9% to US$227b; a third successive year of growth
Biotech market capitalization increased by 28.8% to reach $1.65t, with the industry’s total raised capital also increasing by 26%
Average deal size reached its highest level in five years, and deals of US$5b or more in value accounted for 59% of spend, compared to a five-year average of 51%.